Perrigo Company PLC might’ve been expected in its first quarterly results since launching its Opill OTC oral contraceptive in the US to highlight the early sales and the long-term impact from that historic US first.
Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results
Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.